focus -WSS

focus

author：knowledge 2025-09-06 04:15:34 - browse：117

Outgoing Bristol CEO Giovanni Caforio Emilie Pickering for STAT

It’s changing of the guard time at pharmaceutical giant Bristol Myers Squibb. On Wednesday, CEO Giovanni Caforio will step down. He’ll be replaced by Christopher Boerner, who is currently chief operating officer.

When Caforio took over in May 2015, Bristol was known as a big pharmaceutical firm with the high-flying stock of a biotechnology company, largely due to its role as the company that brought cancer immunotherapy to market. But Bristol stumbled in 2016 when its immunotherapy Opdivo failed to help patients with non-small cell cancer more than chemotherapy. Opdivo remained a big seller, but its failure allowed Merck’s rival Keytruda to move into position to become the best-selling medicine in the world. In 2019, Caforio tried to flip the script, buying the biotech Celgene for $74 billion.

STAT recently sat down with Caforio, 59, to look back on what went wrong and right with his tenure. He also reflected on what it meant to be a physician — and the son of a physician. “We were speaking about patient stories over lunch and dinner, when I was a kid, and I think that drove my passion for medicine,” he said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Snackable artificial intelligence, expert AI, and the pharma industry

WSS

‘The Bear’ and hospitality in hospitals

Zapping the brain for stroke rehab: Pivotal clinical trial begins

More regulation could be coming for drug ads

Ethical issues complicate the benefits of medical crowdfunding

How generative AI is inspiring dreams of a health data revolution

In venture capital firm's success, lessons for turning crisis into profit

knowledge

focus

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

What American doctors can learn from their Israeli counterparts

Supreme Court strikes down use of affirmative action

More regulation could be coming for drug ads

BioMarin wins approval for gene therapy to treat hemophilia A

A year after a Russian missile took her leg, a young Ukrainian gymnast's spirit endures

In age of alternative facts, a scholarly course on calling out crap

A year after a Russian missile took her leg, a young Ukrainian gymnast's spirit endures

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Covid hospitalizations on the rise, Humana says

leisure time

Ethical issues complicate the benefits of medical crowdfunding

NIH nominee Bertagnolli will get October confirmation hearing

House transparency, PBM reform bill gains bipartisan support

How to fix cancer clinical trials' diversity problem

Advances in CAR

Can Threads overtake X, formerly known as Twitter? Experts weigh in.

explore

focus

leisure time

focus